Pharma Icebreaker Panel Discussion: Investing into Immune Rest, Rebalance & Reconstitution

• Which stage of development is most appealing in Immunology?
• What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
• When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
• Which diseases do you think are most promising for B-cell targeted therapies?

Speakers:

Saifur Rahman

District Manager

Sanofi

David Blair

Director, Strategic Partnering (Immunology), Global BD&L

Boehringer Ingelheim

Nikhil Mutyal

Head of Search and Evaluation- Respiratory and Immunology

AstraZeneca

Julie Di Paolo

Senior Director, Immunology Therapeutic Area Lead

Johnson & Johnson

Christopher Tan

Executive Director BD&L, Infectious Disease, Vaccines, Oncology

Merck & Co

Mike Jones

Search & Evaluation Lead, GI & Inflammation, Strategy & Portfolio Development

Takeda Pharmaceutical

Daniel Abernathy

Director - Strategic Research & Development

Otsuka America Pharmaceutical, Inc

Anna Rivkin

Chief Business Officer

Foghorn Therapeutics